Reevaluating the Risk of Serious Adverse Events of Carbonic Anhydrase Inhibitors-Reply

Marko M Popovic¹, Matthew B Schlenker^{1

2

3

4}, Donald A Redelmeier^{5

6

7}

Affiliations

¹ Department of Ophthalmology & Vision Sciences, University of Toronto, Toronto, Ontario, Canada.
² Kensington Vision and Research Centre, Toronto, Ontario, Canada.
³ Toronto Western Hospital, University Health Network, Toronto, Ontario, Canada.
⁴ Trillium Health Partners, Institute for Better Health, Toronto, Ontario, Canada.
⁵ Evaluative Clinical Sciences Program, Sunnybrook Research Institute, Toronto, Ontario, Canada.
⁶ Institute for Clinical Evaluative Sciences in Ontario, Toronto, Ontario, Canada.
⁷ Department of Medicine, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada.

Comment

Marko M Popovic et al. JAMA Ophthalmol. 2022.

. 2022 Jul 1;140(7):746-747.

doi: 10.1001/jamaophthalmol.2022.1568.

Marko M Popovic¹, Matthew B Schlenker^{1

2

3

4}, Donald A Redelmeier^{5

6

7}

¹ Department of Ophthalmology & Vision Sciences, University of Toronto, Toronto, Ontario, Canada.
² Kensington Vision and Research Centre, Toronto, Ontario, Canada.
³ Toronto Western Hospital, University Health Network, Toronto, Ontario, Canada.
⁴ Trillium Health Partners, Institute for Better Health, Toronto, Ontario, Canada.
⁵ Evaluative Clinical Sciences Program, Sunnybrook Research Institute, Toronto, Ontario, Canada.
⁶ Institute for Clinical Evaluative Sciences in Ontario, Toronto, Ontario, Canada.
⁷ Department of Medicine, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada.

No abstract available

Comment on

Serious Adverse Events of Oral and Topical Carbonic Anhydrase Inhibitors.
Popovic MM, Schlenker MB, Thiruchelvam D, Redelmeier DA. Popovic MM, et al. JAMA Ophthalmol. 2022 Mar 1;140(3):235-242. doi: 10.1001/jamaophthalmol.2021.5977. JAMA Ophthalmol. 2022. PMID: 35084437 Free PMC article.
Reevaluating the Risk of Serious Adverse Events of Carbonic Anhydrase Inhibitors.
Bleicher ID, Rossin EJ, Vavvas DG. Bleicher ID, et al. JAMA Ophthalmol. 2022 Jul 1;140(7):745-746. doi: 10.1001/jamaophthalmol.2022.1565. JAMA Ophthalmol. 2022. PMID: 35616947 No abstract available.